Nicht-Vitamin-K-abhängige orale Antikoagulanzien (NOAK) bei chronischer Niereninsuffizienz [Non-vitamin K antagonist oral anticoagulants (NOAC) in chronic kidney disease]


  • G. Schlieper
  • A. Remppis
  • V. Schwenger
  • T. Keller
  • R. Dechend
  • S. Massberg
  • S. Baldus
  • T. Weinreich
  • G. Hetzel
  • J. Floege
  • J. Hoyer
  • F. Mahfoud
  • D. Fliser


  • Nephrologe


  • Nephrologe 13 (2): 91-98


  • Non-vitamin K antagonist oral anticoagulants (NOAC) are administered for stroke prophylaxis in patients with atrial fibrillation and corresponding risk scores. In addition, NOAC are used for treatment and prophylaxis of venous thromboembolic events, such as deep vein thrombosis and acute pulmonary embolism and their prophylaxis in recurrent events. Clinical trials have excluded patients with advanced chronic kidney disease; therefore, data cannot always be generalized to patients with chronic kidney disease. The use of NOAC is not recommended or is contraindicated in advanced stages of chronic kidney disease.